Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35452083.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0279.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen. See related articles by Konopleva et al., p. 2744 and Pollyea et al., p. 2753.
Medical subject headings
- Dancing
- Leukemia, Myeloid, Acute